- Home
- HUT vs RNA Comparison
HUT vs RNA Comparison
Compare HUT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HUT | RNA |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HUT | RNA |
|---|---|---|
| Price | $43.88 | $72.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 20 |
| Target Price | $51.08 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 7.1M | 2.6M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $178,318,000.00 | $20,868,000.00 |
| Revenue This Year | $74.79 | $64.11 |
| Revenue Next Year | $116.78 | $37.25 |
| P/E Ratio | $23.55 | ★ N/A |
| Revenue Growth | 5.60 | ★ 106.27 |
| 52 Week Low | $10.04 | $21.51 |
| 52 Week High | $57.29 | $72.61 |
Technical Indicators
Market Signals| Indicator | HUT | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.58 | 77.11 |
| Support Level | $38.36 | $71.18 |
| Resistance Level | $45.64 | $71.79 |
| Average True Range (ATR) | 4.49 | 0.31 |
| MACD | -0.04 | -0.42 |
| Stochastic Oscillator | 74.71 | 82.89 |
Price Performance
Historical ComparisonAbout HUT Hut 8 Corp.
Hut 8 Corp is an energy infrastructure operator and Bitcoin miner with self-mining, hosting, managed services, and traditional data center operations across North America. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.